Skip to Content

Tranylcypromine Disease Interactions

There are 22 disease interactions with tranylcypromine:

Major

MAOI antidepressants (applies to tranylcypromine) blood pressure

Major Potential Hazard, High plausibility. Applicable conditions: Cerebral Vascular Disorder, Cardiovascular Disease, Hypotension

The use of monoamine oxidase inhibitor (MAOI) antidepressants is contraindicated in patients with cerebrovascular or cardiovascular disease, including hypertension and congestive heart failure. Nonspecific MAOIs inhibit the breakdown of pressor amines, the accumulation of which can precipitate hypertensive crises. Intracranial hemorrhage and death have resulted in some cases. MAOI antidepressants are also commonly associated with dose-related orthostatic hypotension, which occurs most frequently in patients with preexisting hypertension but may be minimized with slow, gradual titration. Blood pressure should be monitored closely in all patients who receive MAOI therapy, and patients should be advised to stop taking the medication and seek medical attention immediately if signs and symptoms of a hypertensive reaction occur (e.g., occipital headache which may radiate frontally; palpitation; neck stiffness or soreness; nausea or vomiting; perspiration associated with fever or cold, clammy skin; mydriasis; photophobia; constricting chest pain).

References

  1. "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.
  2. Golwyn DH, Sevlie CP "Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension." J Clin Psychopharmacol 13 (1993): 77-8
  3. Fallon B, Foote B, Walsh BT, Roose SP "'Spontaneous' hypertensive episodes with monoamine oxidase inhibitors." J Clin Psychiatry 49 (1988): 163-5
  4. Evans DL, Davidson J, Raft D "Early and late side effects of phenelzine." J Clin Psychopharmacol 2 (1982): 208-10
  5. "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.
  6. Keck PE Jr, Vuckovic A, Pope HG Jr, Nierenberg AA, Gribble GW, White K "Acute cardiovascular response to monoamine oxidase inhibitors: a prospective assessment." J Clin Psychopharmacol 9 (1989): 203-6
  7. Linet LS "Mysterious MAOI hypertensive episodes." J Clin Psychiatry 47 (1986): 563-5
  8. Rabkin J, Quitkin F, Harrison W, Tricamo E, McGrath P "Adverse reactions to monoamine oxidase inhibitors. Part I. A comparative study." J Clin Psychopharmacol 4 (1984): 270-8
  9. "Product Information. Parnate (tranylcypromine)." SmithKline Beecham, Philadelphia, PA.
  10. Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH "Blood pressure effects of phenelzine." J Clin Psychopharmacol 3 (1983): 307-10
  11. Rabkin JG, Quitkin FM, McGrath P, Harrison W, Tricamo E "Adverse reactions to monoamine oxidase inhibitors. Part II. Treatment correlates and clinical management." J Clin Psychopharmacol 5 (1985): 2-9
  12. Robinson DS, Nies A, Corcella J, Cooper TB, Spencer C, Keefover R "Cardiovascular effects of phenelzine and amitriptyline in depressed outpatients." J Clin Psychiatry 43 (1982): 8-15
View all 12 references
Major

MAOI antidepressants (applies to tranylcypromine) carcinoid syndrome

Major Potential Hazard, High plausibility.

The use of nonspecific monoamine oxidase inhibitors (MAOIs) is contraindicated in patients with carcinoid syndrome. Nonspecific MAOIs inhibit the breakdown of pressor amines, including serotonin, and may exacerbate symptoms of the syndrome.

References

  1. "Multum Information Services, Inc. Expert Review Panel"
Major

MAOI antidepressants (applies to tranylcypromine) headaches

Major Potential Hazard, High plausibility.

The use of monoamine oxidase inhibitor (MAOI) antidepressants is contraindicated in patients with a history of headaches. Nonspecific MAOIs inhibit the breakdown of pressor amines, the accumulation of which can precipitate hypertensive crises. Intracranial hemorrhage and death have resulted in some cases. Since headache may often be the first symptom of a hypertensive reaction during MAOI therapy, use of these agents is not recommended in patients who experience frequent or severe headaches. MAOIs should be withdrawn promptly if headaches develop during treatment.

References

  1. "Product Information. Parnate (tranylcypromine)." SmithKline Beecham, Philadelphia, PA.
  2. Rabkin J, Quitkin F, Harrison W, Tricamo E, McGrath P "Adverse reactions to monoamine oxidase inhibitors. Part I. A comparative study." J Clin Psychopharmacol 4 (1984): 270-8
  3. Golwyn DH, Sevlie CP "Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension." J Clin Psychopharmacol 13 (1993): 77-8
  4. Fallon B, Foote B, Walsh BT, Roose SP "'Spontaneous' hypertensive episodes with monoamine oxidase inhibitors." J Clin Psychiatry 49 (1988): 163-5
  5. "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.
  6. Evans DL, Davidson J, Raft D "Early and late side effects of phenelzine." J Clin Psychopharmacol 2 (1982): 208-10
  7. Robinson DS, Nies A, Corcella J, Cooper TB, Spencer C, Keefover R "Cardiovascular effects of phenelzine and amitriptyline in depressed outpatients." J Clin Psychiatry 43 (1982): 8-15
  8. Rabkin JG, Quitkin FM, McGrath P, Harrison W, Tricamo E "Adverse reactions to monoamine oxidase inhibitors. Part II. Treatment correlates and clinical management." J Clin Psychopharmacol 5 (1985): 2-9
  9. "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.
  10. Keck PE Jr, Vuckovic A, Pope HG Jr, Nierenberg AA, Gribble GW, White K "Acute cardiovascular response to monoamine oxidase inhibitors: a prospective assessment." J Clin Psychopharmacol 9 (1989): 203-6
  11. Linet LS "Mysterious MAOI hypertensive episodes." J Clin Psychiatry 47 (1986): 563-5
View all 11 references
Major

MAOI antidepressants (applies to tranylcypromine) hyperthyroidism

Major Potential Hazard, High plausibility.

Nonspecific monoamine oxidase inhibitors (MAOIs) inhibit the breakdown of pressor amines, the accumulation of which can precipitate hypertensive crises. Intracranial hemorrhage and death have resulted in some cases. Therapy with nonspecific MAOIs should be administered cautiously in patients with hyperthyroidism, since these patients have an increased sensitivity to pressor amines. Blood pressure should be monitored closely during therapy, and patients should be advised to stop taking the medication and seek medical attention immediately if signs and symptoms of a hypertensive reaction occur (e.g., occipital headache which may radiate frontally; palpitation; neck stiffness or soreness; nausea or vomiting; perspiration associated with fever or cold, clammy skin; mydriasis; photophobia; constricting chest pain).

References

  1. Fallon B, Foote B, Walsh BT, Roose SP "'Spontaneous' hypertensive episodes with monoamine oxidase inhibitors." J Clin Psychiatry 49 (1988): 163-5
  2. Evans DL, Davidson J, Raft D "Early and late side effects of phenelzine." J Clin Psychopharmacol 2 (1982): 208-10
  3. Rabkin JG, Quitkin FM, McGrath P, Harrison W, Tricamo E "Adverse reactions to monoamine oxidase inhibitors. Part II. Treatment correlates and clinical management." J Clin Psychopharmacol 5 (1985): 2-9
  4. Robinson DS, Nies A, Corcella J, Cooper TB, Spencer C, Keefover R "Cardiovascular effects of phenelzine and amitriptyline in depressed outpatients." J Clin Psychiatry 43 (1982): 8-15
  5. Linet LS "Mysterious MAOI hypertensive episodes." J Clin Psychiatry 47 (1986): 563-5
  6. "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.
  7. Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH "Blood pressure effects of phenelzine." J Clin Psychopharmacol 3 (1983): 307-10
  8. Rabkin J, Quitkin F, Harrison W, Tricamo E, McGrath P "Adverse reactions to monoamine oxidase inhibitors. Part I. A comparative study." J Clin Psychopharmacol 4 (1984): 270-8
  9. "Product Information. Parnate (tranylcypromine)." SmithKline Beecham, Philadelphia, PA.
  10. "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.
  11. Keck PE Jr, Vuckovic A, Pope HG Jr, Nierenberg AA, Gribble GW, White K "Acute cardiovascular response to monoamine oxidase inhibitors: a prospective assessment." J Clin Psychopharmacol 9 (1989): 203-6
View all 11 references
Major

MAOI antidepressants (applies to tranylcypromine) liver disease

Major Potential Hazard, High plausibility.

The use of monoamine oxidase inhibitor (MAOI) antidepressants is contraindicated in patients with abnormal liver function tests or a history of liver disease. A low incidence of altered liver function or hepatocellular jaundice has been reported in association with the use of MAOI antidepressants. Periodic monitoring of liver function tests is recommended during prolonged and/or high-dose therapy.

References

  1. Gomezgil E, Salmeron JM, Mas A "Phenelzine-induced fulminant hepatic failure." Ann Intern Med 124 (1996): 692-3
  2. Bonkovsky HL, Blanchette PL, Schned AR "Severe liver injury due to phenelzine with unique hepatic deposition of extracellular material." Am J Med 80 (1986): 689-92
  3. "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.
  4. Robinson DS, Kurtz NM "What is the degree of risk of hepatotoxicity for depressed patients receiving phenelzine therapy? Is the risk sufficient to require that we modify the written advice (as to diet and risks) that we regularly give our patients before we institute this..." J Clin Psychopharmacol 7 (1987): 61-2
  5. "Product Information. Parnate (tranylcypromine)." SmithKline Beecham, Philadelphia, PA.
  6. Zimmerman HJ, Ishak KG "The hepatic injury of monoamine oxidase inhibitors." J Clin Psychopharmacol 7 (1987): 211-3
  7. "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.
View all 7 references
Major

MAOI antidepressants (applies to tranylcypromine) pheochromocytoma

Major Potential Hazard, High plausibility.

The use of nonspecific monoamine oxidase inhibitors (MAOIs) is contraindicated in patients with pheochromocytoma or other tumors of the adrenal medulla, such as some neuroblastomas, that secrete pressor substances. Nonspecific MAOIs inhibit the breakdown of pressor amines, the accumulation of which can precipitate hypertensive crises. Intracranial hemorrhage and death have resulted in some cases.

References

  1. Keck PE Jr, Vuckovic A, Pope HG Jr, Nierenberg AA, Gribble GW, White K "Acute cardiovascular response to monoamine oxidase inhibitors: a prospective assessment." J Clin Psychopharmacol 9 (1989): 203-6
  2. Linet LS "Mysterious MAOI hypertensive episodes." J Clin Psychiatry 47 (1986): 563-5
  3. "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.
  4. Fallon B, Foote B, Walsh BT, Roose SP "'Spontaneous' hypertensive episodes with monoamine oxidase inhibitors." J Clin Psychiatry 49 (1988): 163-5
  5. Evans DL, Davidson J, Raft D "Early and late side effects of phenelzine." J Clin Psychopharmacol 2 (1982): 208-10
  6. "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.
  7. Rabkin J, Quitkin F, Harrison W, Tricamo E, McGrath P "Adverse reactions to monoamine oxidase inhibitors. Part I. A comparative study." J Clin Psychopharmacol 4 (1984): 270-8
  8. "Product Information. Parnate (tranylcypromine)." SmithKline Beecham, Philadelphia, PA.
  9. Robinson DS, Nies A, Corcella J, Cooper TB, Spencer C, Keefover R "Cardiovascular effects of phenelzine and amitriptyline in depressed outpatients." J Clin Psychiatry 43 (1982): 8-15
  10. Rabkin JG, Quitkin FM, McGrath P, Harrison W, Tricamo E "Adverse reactions to monoamine oxidase inhibitors. Part II. Treatment correlates and clinical management." J Clin Psychopharmacol 5 (1985): 2-9
View all 10 references
Major

MAOI antidepressants (applies to tranylcypromine) renal dysfunction

Major Potential Hazard, High plausibility.

The use of monoamine oxidase inhibitor (MAOI) antidepressants is contraindicated in patients with severe renal dysfunction. These drugs may accumulate in plasma when renal function is impaired.

References

  1. "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.
  2. "Product Information. Parnate (tranylcypromine)." SmithKline Beecham, Philadelphia, PA.
  3. "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.
Major

Monoamine oxidase inhibitors (applies to tranylcypromine) alcohol

Major Potential Hazard, Moderate plausibility. Applicable conditions: Alcoholism

The use of monoamine oxidase inhibitors with alcohol or any other CNS depressants is contraindicated.

Major

Monoamine oxidase inhibitors (applies to tranylcypromine) depression

Major Potential Hazard, Moderate plausibility. Applicable conditions: Psychosis

Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior. Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes. Families and caregivers should be advised of the need for close observation and communication with the treating physician. Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset. It may be prudent to refrain from dispensing large quantities of medication to these patients.

Major

Monoamine oxidase inhibitors (applies to tranylcypromine) hypertension/CVD

Major Potential Hazard, Moderate plausibility. Applicable conditions: Cardiovascular Disease, Cerebral Vascular Disorder, Congestive Heart Failure

The use of most monoamine oxidase inhibitors (MAOIs) is contraindicated in patients with diagnosed cardiovascular disease, hypertension, or confirmed or suspected cerebrovascular disorders. These drugs can cause hypertensive crises, which sometimes can be fatal, and are characterized by occipital headache, palpitations, neck stiffness or soreness, nausea, sweating, dilated pupils and photophobia. Intracranial bleeding has been reported in some cases in association with the increase in blood pressure.

Normotensive patients receiving therapy with MAOIs need to have monitored their blood pressure frequently to detect any evidence of pressor response and treatment should be discontinued immediately if blood pressure increases or the patient reports symptoms such a headaches or palpitations. Additionally, patients should be advised to avoid foods and drinks with high tyramine content such as cheese, sour cream, beer, liver, bananas and others, as these might trigger an hypertensive crisis.

Major

Monoamine oxidase inhibitors (applies to tranylcypromine) liver disease

Major Potential Hazard, Moderate plausibility.

The use of monoamine oxidase inhibitors is contraindicated in patients with a history of liver disease or in those with abnormal liver function tests.

Major

Monoamine oxidase inhibitors (applies to tranylcypromine) pheochromocytoma

Major Potential Hazard, Moderate plausibility.

The use of most monoamine oxidase inhibitors (MAOIs) is contraindicated in patients with pheochromocytoma, as such tumors secrete pressor substances whose metabolism may be inhibited by these drugs.

Moderate

MAOI antidepressants (applies to tranylcypromine) hypoglycemia

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Diabetes Mellitus

There is conflicting evidence regarding whether monoamine oxidase inhibitors (MAOIs) affect glucose metabolism or potentiate oral hypoglycemic agents. Therapy with MAOIs should be administered cautiously in patients with diabetes.

References

  1. "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.
  2. "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.
  3. "Product Information. Parnate (tranylcypromine)." SmithKline Beecham, Philadelphia, PA.
Moderate

MAOI antidepressants (applies to tranylcypromine) parkinsonism

Moderate Potential Hazard, Moderate plausibility.

Nonspecific monoamine oxidase inhibitors (MAOIs) may increase the frequency and severity of signs and symptoms associated with parkinsonian syndrome. Therapy with nonspecific MAOIs should be administered cautiously in patients with this disorder.

References

  1. "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.
  2. Teusink JP, Alexopoulos GS, Shamoian CA "Parkinsonian side effects induced by a monoamine oxidase inhibitor." Am J Psychiatry 141 (1984): 118-9
  3. "Product Information. Parnate (tranylcypromine)." SmithKline Beecham, Philadelphia, PA.
  4. Gillman MA, Sandyk R "Parkinsonism induced by a monoamine oxidase inhibitor." Postgrad Med J 62 (1986): 235-6
  5. "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.
View all 5 references
Moderate

MAOI antidepressants (applies to tranylcypromine) schizophrenia/bipolar

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Bipolar Disorder, Mania

Monoamine oxidase inhibitor (MAOI) antidepressants may cause excessive stimulation in hyperactive or schizophrenic patients. Symptoms of psychosis may be aggravated in schizophrenia, particularly that with paranoid symptomatology. Depressed patients, usually those with bipolar disorder, may experience a switch from depression to mania or hypomania. Therapy with MAOI antidepressants should be administered cautiously in patients with hyperactive or hyperexcitable personalities, schizophrenia or bipolar disorder.

References

  1. "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.
  2. "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.
  3. "Product Information. Parnate (tranylcypromine)." SmithKline Beecham, Philadelphia, PA.
Moderate

MAOI antidepressants (applies to tranylcypromine) seizures

Moderate Potential Hazard, Moderate plausibility.

Monoamine oxidase inhibitor (MAOI) antidepressants may have variable effects on seizure threshold. Decreased seizure frequency as well as increased frequency have been reported. Therapy with MAOI antidepressants should be administered cautiously in patients with a history of seizures.

References

  1. "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.
  2. "Product Information. Parnate (tranylcypromine)." SmithKline Beecham, Philadelphia, PA.
  3. Waghray SN, Francis K "Epilepsy as an adverse reaction to combined therapy of MAOIs and tricyclics." J R Soc Med 77 (1984): 346
  4. Pascual J, Combarros O, Berciano J "Partial status epilepticus following single low dose of chlorimipramine in a patient on MAO-inhibitor treatment." Clin Neuropharmacol 10 (1987): 565-7
  5. "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.
View all 5 references
Moderate

Monoamine oxidase inhibitors (applies to tranylcypromine) angina

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Angina Pectoris, Myocardial Infarction

Monoamine oxidase inhibitors may have the capacity to suppress anginal pain that would otherwise serve as a warning of myocardial ischemia. Caution is advised in patients with a history of angina or risk of myocardial infarction.

Moderate

Monoamine oxidase inhibitors (applies to tranylcypromine) bipolar disorder screening

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Depression

A major depressive episode can be the initial presentation of bipolar disorder. Patients with depressive symptoms should be adequately screened to determine if they are at risk for bipolar disorder prior to initiating treatment with a monoamine oxidase inhibitor (MAOI). This screening should include a detailed psychiatric history, including a family history of suicide, bipolar disorder, and depression. It should be noted that MAOIs antidepressants are not approved for use in treating bipolar depression.

Moderate

Monoamine oxidase inhibitors (applies to tranylcypromine) diabetes

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Diabetes Mellitus

Monoamine oxidase inhibitors can increase the sensitivity to insulin, and have contributed to hypoglycemic episodes in patients with diabetes. Caution should be used when prescribing in diabetic patients.

Moderate

Monoamine oxidase inhibitors (applies to tranylcypromine) hypotension

Moderate Potential Hazard, Moderate plausibility.

Hypotension has been observed during therapy with monoamine oxidase inhibitors. These drugs should be used with caution, especially in patients with tendency towards hypotension or taking other drugs known to cause hypotension.

Moderate

Monoamine oxidase inhibitors (applies to tranylcypromine) renal disease

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction

Monoamine oxidase inhibitors should be used with caution in patients with renal impairment as there is a possibility of cumulative effects in such patients. Dose selection should be cautious, usually starting at the low end of the dosing range.

Moderate

Monoamine oxidase inhibitors (applies to tranylcypromine) seizures

Moderate Potential Hazard, Moderate plausibility.

Monoamine oxidase inhibitors have shown a variable effect on the convulsive threshold. Caution should be used when treating patients with epilepsy.

Tranylcypromine drug interactions

There are 513 drug interactions with tranylcypromine

Tranylcypromine alcohol/food interactions

There is 1 alcohol/food interaction with tranylcypromine

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.